I read a remarkable story last month about a new cancer drug that was just approved by the U.S. Food and Drug Administration (FDA). The drug is called daraxonrasib, marketed under the brand name Rasonque, and it was developed by Revolution Medicines.
What caught my attention was not only what this new medicine can do for patients with advanced pancreatic cancer, but also what it costs.
Rasonque has a wholesale list price of approximately $39,800 for a 30-day supply, or roughly $478,000 for a year of treatment. That works out to more than $1,300 per day.
When I first read this, my reaction was one of amazement and then concern.
How can a pill that may give a person precious additional months of life cost nearly half a million dollars a year?
But before criticizing the price, we should first understand why this particular drug is attracting so much attention.
A New Hope for Pancreatic Cancer
Pancreatic cancer has long been one of the most difficult cancers to treat. It is frequently discovered only after it has advanced, and treatment options for patients whose disease has progressed after chemotherapy have historically been limited.
That is why the FDA's approval of Rasonque is so significant.
Rasonque is the first approved therapy that broadly targets RAS in metastatic pancreatic adenocarcinoma. RAS is a family of proteins involved in controlling cell growth, and abnormal RAS signaling plays a major role in most pancreatic cancers.
The clinical results are impressive. In a Phase 3 clinical trial involving 500 patients with metastatic pancreatic cancer, those receiving Rasonque had a median overall survival of 13.2 months, compared with 6.7 months for patients receiving standard chemotherapy.
In other words, the new treatment nearly doubled median survival.
For a healthy person, an additional six months may not sound like a very long time.
For someone with advanced cancer and for that person's family, six additional months can mean something entirely different.
Six more months of birthdays. Six more months of conversations with children and grandchildren.
Six more months to see a family wedding. Six more months to say goodbye.
Sometimes, we cannot measure the value of life in dollars.
The Miracle Has a Price
This is where the story becomes complicated. Scientific progress has never been inexpensive.
Behind a successful drug are years of laboratory research, failed experiments, clinical trials, scientists, physicians, regulatory reviews, manufacturing facilities and enormous financial investments. Many experimental drugs never reach the market.
As someone who spent much of my professional career in pharmaceutical chemistry and later worked at the FDA reviewing drug products, I understand that bringing a new medicine from the laboratory to patients is an extraordinarily complicated process.
I also understand the importance of rewarding scientific innovation.
But I have always believed that there is another side to the equation.
A medicine can be scientifically revolutionary and still be financially difficult for society to afford. That is the dilemma we face today.
Who Pays $478,000?
The $478,000 annual figure is the list price, not necessarily what every patient or insurer ultimately pays.
Insurance coverage, negotiated discounts, government programs and pharmaceutical assistance can reduce the actual amount paid.
Nevertheless, the list price tells us something important about the direction in which modern cancer treatment is moving.
Specialty cancer medicines are becoming increasingly expensive.
We are entering an era in which some of the most sophisticated medicines are designed to target a specific genetic mutation or molecular pathway inside a cancer cell.
This is wonderful science. Instead of simply attacking rapidly dividing cells, as many older chemotherapy drugs do, targeted therapies attempt to interfere with the biological machinery that allows cancer to grow.
This is the future of medicine. But the future of medicine must also be the future of affordable medicine.
Can We Put a Price on More Life?
This question is particularly difficult for me because I have lived long enough to see how dramatically medicine has changed.
When I was growing up in the Philippines, many diseases that are routinely treated today could be life-threatening.
When I came to the United States in 1960, medical technology was already advancing rapidly. Over the decades I have watched antibiotics, vaccines, imaging technologies, cancer treatments, transplantation, biotechnology and molecular medicine transform the practice of medicine.
Today, scientists can look inside a cancer cell and identify the molecular signals that make it grow. That is almost unimaginable compared with the medicine of my childhood.
And yet, I sometimes wonder whether our scientific ability is advancing faster than our ability to make these discoveries accessible to everyone.
A revolutionary medicine that only wealthy patients can realistically obtain creates another kind of inequality.
The Global Question
This issue is especially important to me because my blog has readers around the world.
The United States is fortunate to have one of the world's most advanced biomedical research systems. Many of the world's breakthrough medicines originate here.
But the American system also produces some of the highest drug prices in the world.
What happens to a patient in the Philippines? What about a cancer patient in India, Indonesia, Vietnam or Africa?
What about a retired person living on a fixed income?
What happens when the medicine that might extend someone's life costs more in one year than many families earn in a lifetime?
These are not merely American questions. They are global questions.
Medical science belongs, in some sense, to all humanity. But the economics of medical science often determine who gets to benefit from it.
I Am Not Against Pharmaceutical Companies
I want to make one thing clear. I am not opposed to pharmaceutical companies making a profit.
Quite the opposite. I spent many years working in pharmaceutical research and regulation, and I know firsthand how much scientific knowledge, investment and human effort are required to develop new medicines.
Without financial incentives, much of the research that produces tomorrow's cures might never happen.
The question is not whether pharmaceutical companies should make money.
The question is how much is enough and how do we balance a company's investment and reward with society's responsibility to make life-saving medicines accessible?
That is a much more difficult question.
A Remarkable Beginning
For now, I prefer to celebrate the scientific achievement behind Rasonque.
The FDA's approval represents an important milestone in cancer treatment. For patients with metastatic pancreatic cancer who have already received treatment or who cannot tolerate intensive combination chemotherapy, this drug offers another option.
And that is something worth celebrating. Perhaps Rasonque will be the beginning of a new generation of treatments that can do even more.
Perhaps today's 13.2 months of median survival will eventually become several years.
Perhaps another generation of scientists will discover ways to turn pancreatic cancer from a devastating disease into a manageable one.
That is how medical progress works. One discovery builds upon another.
But We Must Ask the Hard Questions
At the same time, I believe we should continue asking difficult questions about the cost of these discoveries.
Can we develop breakthrough medicines without making them financially out of reach?
Can governments, pharmaceutical companies and insurance companies find a better balance between innovation and affordability?
Can the world's wealthier nations help make revolutionary treatments available to patients in poorer countries?
And perhaps the most important question: What is the value of an additional year of life?
There is no simple answer. For a pharmaceutical company, it may be measured in research costs, manufacturing expenses and return on investment.
For an insurance company, it may be measured in actuarial calculations.
For a government, it may become a question of health-care budgets.
But for a husband, wife, father, mother, grandfather or grandmother facing terminal cancer, an additional year may be priceless.
That is the paradox of modern medicine. Science is learning how to give us more time.
Our challenge as a society is to make sure that the price of that additional time does not become so high that only a fortunate few and the rich can afford it.
For me, that is the real story behind this remarkable new cancer pill.
AI Impressions on this Posting:
This is an especially strong topic for your blog because it brings together medical science, pharmaceutical innovation, the economics of health care, and a very human question: How much should a life-saving medicine cost?
I checked the story against the FDA and recent reporting. One important correction to the article you read: the FDA says Rasonque is a once-daily tablet, and Revolution Medicines lists the wholesale acquisition cost at $39,800 for a 30-day supply, or about $478,000 a year before insurance and other discounts. The FDA approved it on August 26, 2026, for certain adults with metastatic pancreatic adenocarcinoma.
The clinical results are remarkable: in the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with Rasonque versus 6.7 months with standard chemotherapy.
Finally, I believe this topic fits your worldwide readership particularly well because it moves beyond “a new cancer drug was approved” into the much larger question of what medical progress means when life-saving innovation becomes extraordinarily expensive.
- Inavolisib (Itovebi) (Approved late 2024): Oral PI3K inhibitor for advanced HR-positive, HER2-negative breast cancer.
- Revumenib (Revuforj) (Approved late 2024): First-in-class menin inhibitor for relapsed or refractory acute leukemia.
- Zanidatamab (Ziihera) (Approved late 2024/expanded 2026): For HER2-positive biliary tract and gastrointestinal adenocarcinomas.
- Vepdegestrant (Approved mid-2026): First-in-class PROTAC degrader therapy for advanced breast cancer.
- Without Insurance: Specialty oncology drugs generally cost $150,000 to $300,000+ annually; complex infused biologics or CAR-T therapies can exceed $500,000.
- With Commercial Insurance: Out-of-pocket expenses depend on your deductible, coinsurance, or copay tiers. Most commercial plans cap annual in-network out-of-pocket maximums.
- With Medicare: Beneficiaries utilizing Part D or Part B specialty oncology drugs have out-of-pocket spending limits under modern Medicare provisions, though co-pays prior to caps can still present barriers.
- Manufacturer Co-Pay Cards: Most pharmaceutical companies (such as Genentech, Merck, and Novartis) offer co-pay assistance cards for commercially insured patients to sharply reduce monthly out-of-pocket costs.
- Patient Assistance Programs (PAP): If you are uninsured or your insurance denies coverage, drug makers often supply medications at no charge to qualifying low-to-middle-income individuals.
- Independent Co-Pay Foundations: Nonprofits can assist eligible patients with co-pays, deductibles, and insurance premiums. You can reach out to the CancerCare Co-Payment Assistance Foundation or explore resources via the American Cancer Society.
- Meanwhile, What changes most with age?As people age, several things change, including:
- Values: Things that once seemed important start feeling small, while simple things become priceless.
- Priorities: Time becomes more valuable, and people become less willing to waste hours on arguments, drama, and things that disturb their peace.
- Perspective on relationships: A few genuine relationships become more valuable than a large social circle.
- Self-care: Taking care of oneself becomes less about appearance and more about staying capable.
- Appreciation for life: People appreciate ordinary moments more and understand that life is fleeting.
These changes reflect a shift in focus towards what truly matters in life, such as health, relationships, and personal growth.Finally, Beacon Shines for Veterans Day
The Mount Diablo Beacon will shine Wednesday night, November 11, to honor the veterans who have served our country. Watch for the blinking light atop Mount Diablo from sunset until just after sunrise on Thursday.Originally the beacon guided air traffic, first from a 75-foot tower and then from the top of the Summit Visitor Center. It was turned off in 1940 when the nation entered World War II and not used for navigation again. Since1964 the beacon has been lit every Pearl Harbor Day to honor war veterans.Thanks to a joint proclamation, the Mount Diablo Beacon now also shines on Memorial Day and Veterans Day to honor all veterans. This Veterans Day volunteers from Save Mount Diablo will light the beacon, and the public is invited to join town leaders and local veterans for a ceremony at 4:40pm in front of the Veterans Memorial Building in Danville.
Happy Veterans Day!
No comments:
Post a Comment